Uniqure Nv Aktie - 0EE0

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

31,50

Gebot

0,00

Fragen

0,00

Volumen

427

0,00 Tagesbereich 0,00

31,50 52-Wochen-Bereich 31,50

Marktkapitalisierung

1,507B

Handelsende

31,50

Handelsbeginn

Letzte Trade

15.44926

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

12.613

Ausgegebene Aktien

47.834.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-2,36

Gewinn pro Aktie (EPS)

-6,45

Erlöse

21,9M

Nettogewinn

-308,48M

Sektor

Pharmaceutical Preparations

Branche

Pharmaceutical Preparations

Website

www.uniqure.com

Hauptsitz

Amsterdam, North Holland, Nld

Gegründet

Uniqure Nv is listed in the Pharmaceutical Preparations sector of the Londoner Börse with ticker 0EE0. The last closing price for Uniqure Nv was US$31,50. Over the last year, Uniqure Nv shares have traded in a share price range of US$ 31,50 to US$ 31,50.

Uniqure Nv currently has 47.834.000 shares in issue. The market capitalisation of Uniqure Nv is US$1,51 billion. Uniqure Nv has a price to earnings ratio (PE ratio) of -2.36.

uniQure Announces Pricing of its Public Offering

uniQure Announces Pricing of its Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing...

uniQure Announces Proposed Public Offering

uniQure Announces Proposed Public Offering LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative...

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease ~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing...

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy LEXINGTON, Mass. and AMSTERDAM, Nov. 21...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	31.5	31.5	31.5	1940	31.5	DE
4	31.5	31.5	31.5	2635	31.5	DE
12	31.5	31.5	31.5	12613	31.5	DE
26	31.5	31.5	31.5	8128	31.5	DE
52	31.5	31.5	31.5	8870	31.5	DE
156	31.5	31.5	31.5	3295	31.5	DE
260	31.5	31.5	31.5	2082	31.5	DE

0EE0 - Frequently Asked Questions (FAQ)

What is the current Uniqure Nv share price?

The current share price of Uniqure Nv is US$ 31,50

How many Uniqure Nv shares are in issue?

Uniqure Nv has 47.834.000 shares in issue

What is the market cap of Uniqure Nv?

The market capitalisation of Uniqure Nv is USD 1,51B

What is the 1 year trading range for Uniqure Nv share price?

Uniqure Nv has traded in the range of US$ 31,50 to US$ 31,50 during the past year

What is the PE ratio of Uniqure Nv?

The price to earnings ratio of Uniqure Nv is -2,36

What is the cash to sales ratio of Uniqure Nv?

The cash to sales ratio of Uniqure Nv is 33,24

What is the reporting currency for Uniqure Nv?

Uniqure Nv reports financial results in USD

What is the latest annual turnover for Uniqure Nv?

The latest annual turnover of Uniqure Nv is USD 21,9M

What is the latest annual profit for Uniqure Nv?

The latest annual profit of Uniqure Nv is USD -308,48M

What is the registered address of Uniqure Nv?

The registered address for Uniqure Nv is PAASHEUVELWEG 25A, AMSTERDAM, NORTH HOLLAND, 1105 BP

What is the Uniqure Nv website address?

The website address for Uniqure Nv is www.uniqure.com

Which industry sector does Uniqure Nv operate in?

Uniqure Nv operates in the PHARMACEUTICAL PREPARATIONS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
MACMarechale Capital Plc	3,80p (117,14%)	38,62M
DKEDukemount Capital Plc	0,045p (42,86%)	905,37M
SCGLSealand Capital Galaxy Limited	8,00p (37,93%)	13,92M
OBDOxford Biodynamics Plc	0,65p (30,00%)	5,03M
BKYBerkeley Energia Limited	19,25p (20,31%)	1,06M
NFXNuformix Plc	0,085p (-41,38%)	262,46M
PPSProton Motor Power Systems Plc	0,225p (-25,00%)	983,97k
VASTVast Resources Plc	0,115p (-19,30%)	183,07M
GSCGs Chain Plc	1,30p (-16,13%)	629k
SYMESupply@me Capital Plc	0,0026p (-16,13%)	144,24M
DKEDukemount Capital Plc	0,045p (42,86%)	905,37M
NTVONativo Resources Plc	0,0019p (0,00%)	467,88M
INSPInspirit Energy Holdings Plc	0,0029p (11,54%)	429,63M
MSMNMosman Oil And Gas Limited	0,025p (-3,85%)	401,42M
TRPTower Resources Plc	0,0285p (-3,39%)	303,27M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Uniqure Nv (0EE0)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Uniqure Nv

0EE0 Neueste Nachrichten

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

0EE0 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Uniqure Nv (0EE0) Börsenkurse

Uniqure Nv (0EE0)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Uniqure Nv

0EE0 Neueste Nachrichten

0EE0 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen